Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.61 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.54 |
| ▸ | GRIK1 | P39086 | 9/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 8/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10641706 | 0.89 | SLC7A5 (0.43) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL9545322 | 0.86 | SLC7A5 (0.68) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL600881 | 0.86 | SLC7A5 (0.68) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL29024969 | 0.86 | SLC7A5 (0.68) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| Hydrochloric Acid SCHEMBL8892666 | 0.83 | SLC7A5 (0.65) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL28160788 | 0.82 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL28160789 | 0.82 | SLC7A5 (0.58) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL21120852 | 0.80 | ENPEP (0.54) | SLC7A5SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL17164633 | 0.79 | GSR (0.54) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL16155050 | 0.78 | FOLH1 (0.44) | SLC7A5SLC1A2SLC1A1SLC1A3GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025109220-A1 | METHOD OF PURIFICATION OF ECTOINE AND COMPOSITION THEREOF | METABOLIC EXPLORER (FR) | 2025-05-30 | — | — | WO | disclosed |
| EP-4560023-A1 | METHOD OF PURIFICATION OF ECTOINE AND COMPOSITION THEREOF | Metabolic Explorer (FR) | 2025-05-28 | — | — | EP | disclosed |
| CN-118126913-A | Recombinant escherichia coli for producing ectoin by utilizing aspartic acid as well as construction method and application thereof | 浙江绿创生物科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-114277046-B | Three-gene tandem expression vector for synthesizing tetrahydropyrimidine and application thereof | 河北师范大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-117866866-A | Recombinant escherichia coli for producing exendin by utilizing fumaric acid as well as construction method and application thereof | 浙江绿创生物科技有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-110914435-B | Yeast for producing Exidocrine | 奇华顿股份有限公司 | 2023-10-17 | — | — | CN | disclosed |
| EP-4100540-A1 | MODIFIED MICROORGANISM AND METHOD FOR THE IMPROVED PRODUCTION OF ECTOINE | Metabolic Explorer (FR) | 2022-12-14 | — | — | EP | disclosed |
| CN-115427580-A | Modified microorganisms and methods for improving ectoine production | 代谢探索者公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-114277046-A | Tri-gene tandem expression vector for synthesizing tetrahydropyrimidine and application thereof | 河北师范大学 | 2022-04-05 | — | — | CN | disclosed |
| EP-3833753-A1 | AN IMPROVED METHOD TO PRODUCE CHEMICAL COMPOUNDS DERIVED FROM OXALOACETATE BY MICROORGANISMS | Technische Universität München (DE) | 2021-06-16 | — | — | EP | disclosed |
| US-20180042996-A1 | Hydrogel-Linked IL-1ra Prodrug | ASCENDIS PHARMA OSTEOARTHRITIS DIVISION A/S (DK) | 2018-02-15 | — | — | US | disclosed |
| US-9855340-B2 | Hydrogel prodrugs | ASCENDIS PHARMA A/S (DK) | 2018-01-02 | — | — | US | disclosed |
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | ASCENDIS PHARMA A/S (DK) | 2017-08-10 | — | — | US | disclosed |
| US-20160296600-A1 | Relaxin Prodrugs | ASCENDIS PHARMA RELAXIN DIVISION A/S (DK) | 2016-10-13 | — | — | US | disclosed |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | ASCENDIS PHARMA A/S (DK) | 2016-03-24 | — | — | US | disclosed |
| US-20150297740-A1 | VEGF Neutralizing Prodrugs for the Treatment of Ocular Conditions | ASCENDIS PHARMA INC. | 2015-10-22 | — | — | US | disclosed |
| US-20150290337-A1 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT | ASCENDIS PHARMA INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150258205-A1 | Hydrogel Prodrugs | ASCENDIS PHARMA GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2015-01-08 | — | — | US | disclosed |
| WO-1992002543-A1 | NOVEL IMMUNOSUPPRESSANT PEPTIDES | CYTEL CORPORATION (US) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290337-A1 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT | ADAMTS13, ADAMTS5, TNF | SLC7A5 2549/4885SLC1A2 1546/4885SLC1A1 1517/4885 |
| US-20160296600-A1 | Relaxin Prodrugs | RXFP1, RXFP2, RXFP3 | SLC7A5 1982/4885SLC1A2 1403/4885SLC1A1 1221/4885 |
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | DNPEP, PAM, ASNS | SLC7A5 20/4885SLC1A2 91/4885SLC1A1 61/4885 |
| US-20180042996-A1 | Hydrogel-Linked IL-1ra Prodrug | IL1A, IL1B, IL1R1 | SLC7A5 2461/4885SLC1A2 2629/4885SLC1A1 1174/4885 |
| US-20150258205-A1 | Hydrogel Prodrugs | CD44, DNPH1, PHYKPL | SLC7A5 1416/4885SLC1A2 1706/4885SLC1A1 1479/4885 |
| US-20160082123-A1 | Hydrogel-Linked Prodrugs Releasing Tagged Drugs | PTMS, PGLS, PAM | SLC7A5 2406/4885SLC1A2 2850/4885SLC1A1 2258/4885 |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | SLC7A5 3519/4885SLC1A2 2926/4885SLC1A1 2659/4885 |
| US-20150297740-A1 | VEGF Neutralizing Prodrugs for the Treatment of Ocular Conditions | VEGFA, KDR, FLT1 | SLC7A5 2229/4885SLC1A2 3135/4885SLC1A1 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.